in 2013 it moved its headquarters to cambridge uk and concentrated its r d in three sites cambridge gaithersburg maryland usa location of medimmune for work on biopharmaceuticals and m lndal near gothenburg in sweden for research on traditional chemical drugs astrazeneca has a portfolio of products for major disease areas including cancer cardiovascular gastrointestinal infection neuroscience respiratory and inflammation the company was founded in 1999 through the merger of the swedish astra ab and the english zeneca group itself formed by the demerger of the pharmaceutical operations of imperial chemical industries in 1993 since the merger it has been among the world s largest pharmaceutical companies and has made numerous corporate acquisitions including cambridge antibody technology in 2006 medimmune in 2007 spirogen in 2013 and definiens by medimmune in 2014 astrazeneca has a primary listing on the london stock exchange and is a constituent of the ftse 100 index it has secondary listings on the new york stock exchange and the omx exchange astra ab was founded in 1913 in s dert lje sweden by 400 doctors and apothecaries in 1993 the british chemicals company ici demerged its pharmaceuticals businesses and its agrochemicals and specialities businesses to form zeneca